Covid-19: UK will not buy Evusheld owing to “insufficient data” on protection, government says-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Covid-19: UK will not buy Evusheld owing to “insufficient data” on protection, government says

Published:2022-08-15 Issue: Volume: Page:o2021
ISSN:1756-1833
Container-title:BMJ
language:en
Short-container-title:BMJ

Author:

Mahase Elisabeth

Publisher

BMJ

Subject

General Engineering

Reference3 articles.

1. National Institute for Health and Care Excellence. Research to access pathway for investigational drugs for COVID-19 (RAPID C-19). https://www.nice.org.uk/covid-19/rapid-c19

2. Covid-19: Evusheld is approved in UK for prophylaxis in immunocompromised people

3. Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health Outcomes and Cost-effectiveness of Monoclonal SARS-CoV-2 Antibodies as Pre-exposure Prophylaxis;JAMA Network Open;2023-07-06

2. Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID‐19 in immunocompromised patients;British Journal of Haematology;2023-04-03

3. A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea;Journal of Korean Medical Science;2023

4. Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience;Viruses;2022-12-30

5. AstraZeneca’s covid-19 (mis)adventure and the future of vaccine equity;BMJ;2022-11-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP